Market News & Trends
Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600
Eton Pharmaceuticals, Inc recently announced positive results from its bioequivalence study of ET-600, a proprietary, patented oral solution of desmopressin under development for the treatment…
Gradalis Announces Development of Clinically Relevant Exome Sequencing Bioinformatics Pipeline to Determine Clonal Tumor Mutation Burden
Gradalis, Inc. recently announced a peer-reviewed publication in Scientific Reports. The paper details the methods and validation of Gradalis’ exome sequencing procedure and associated bioinformatics…
Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108
Palisade Bio, Inc. recently provided an update on its ongoing Phase 1a/b study of PALI-2108 for the treatment of Ulcerative Colitis (UC). The Company has…
Polyrizon Signs Non–Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments
Polyrizon Ltd. recently announced it has signed a non-binding Letter of Intent (LOI) with a biotech company focused on psychedelic-derived therapeutics (“the psychedelic company”), to…
Discovery Analysis Demonstrates Transformative Sensitivity of 95% with Specificity of 98% for the Detection of Pancreatic Cancer in Blood Samples
BEMainz Biomed N.V. recently announcedit has entered into a License and Option Agreement (the “Agreement”) with Liquid Biosciences (“Liquid”) to access a portfolio of novel…
Gattefossé Achieves Key Milestone With New US Plant Certifications
Gattefossé, a leading provider of specialty ingredients and formulation solutions for personal care and pharmaceutical industries, proudly announces the successful certification of its new manufacturing…
Kaerus Bioscience Successfully Completes Phase 1 Trial & Demonstrates Proof of Mechanism With its Novel BK Channel Modulator KER-0193 Being Developed for Fragile X Syndrome
Kaerus Bioscience recently announces the successful completion of its Phase 1 clinical trial of KER-0193, a novel BK channel modulator the company is developing for Fragile…
Exogenus Therapeutics Chooses Lonza to Develop a GMP-Compliant Process to Manufacture Exo-101, its Lead Exosome-Based Candidate
Exogenus Therapeutics, a Portuguese biotech company, and Lonza, a global development and manufacturing partner to the pharmaceutical and biotech markets, announced today a collaboration to…
BIOVECTRA is Honored With 2025 CDMO Leadership Award for Biologics
BIOVECTRA, a part of Agilent Technologies Inc., is a leading North American CDMO specializing in biologics, mRNA therapeutics, and complex chemistry, proudly announces it is…
Kaerus Bioscience Successfully Completes Phase 1 Trial & Demonstrates Proof of Mechanism With its Novel BK Channel Modulator Being Developed for Fragile X Syndrome
Kaerus Bioscience recently announced the successful completion of its Phase 1 clinical trial of KER-0193, a novel BK channel modulator the company is developing for…
Shilpa Launches "Hybrid CDMO" at DCAT
Shilpa Medicare launches its new full service "hybrid: CDMO at DCAT 2025. The newly formed CDMO will see Shilpa serve both small and large molecules…
CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced positive results from the…
Curia Announces Strategic Refinancing to Support Continued Growth
Curia Global, Inc. recently announced it has refinanced its senior secured credit facilities. The transaction provides Curia with incremental capital and extends the maturities of…
OKYO Pharma Files for Fast Track Designation With FDA for Urcosimod to Treat Neuropathic Corneal Pain
OKYO Pharma Limited recently announce the filing of its application for Fast Track designation with the U.S. Food and Drug Administration (FDA) for urcosimod (formerly known…
Purple Biotech Granted New Patent for NT219 in Combination With EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets
Purple Biotech Ltd. recently announced the U.S. Patent and Trademark Office has issued a patent for NT219 used in combination with epidermal growth factor receptor…
atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression
atai Life Sciences recently announced the completion of patient enrollment in the eight-week, double-blind, core stage of the global Phase 2b clinical trial evaluating BPL-003 (mebufotenin…
Lisata Therapeutics & GATC Health Consummate First Step in Strategic Collaboration to Use AI to Derisk & Accelerate Drug Development
Lisata Therapeutics, Inc. and GATC Health Corp recently announced the consummation of the first step of an intended multi-part strategic agreement. Under terms of the…
Axplora Expands Commercial Payload Production Capabilities at Le Mans to Strengthen its Leading Position in ADC Manufacturing
Axplora, a global leader in API small molecule and ADC (antibody-drug conjugate) manufacturing, is strengthening its leading position in the commercial manufacturing of ADCs with…
Jupiter Neurosciences & Aquanova AG Announce Strategic Collaboration to Develop Longevity & Healthspan Products
Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL, a patented resveratrol-based platform, today announced a strategic partnership with…
Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments
Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, announced today that it has secured…
